bioAffinity Technologies, Inc. (BIAF) income statement
BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3075% below fair value
$1.65−0.20 (-10.81%)
Close on Nov 20, 2026Market cap $13.37MP/E –Yield –
bioAffinity Technologies, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -209.8%
- Net margin
- -257.3%
- Return on equity, FY2025
- -301.8%
Financial strength
- Current ratio
- 1.44
- Debt to equity
- 0.01
- Debt to assets
- 0.5%
- Cash to current liabilities
- 90.6%
Valuation
- P/E ratio
- –
- Price to sales
- 2.27
- Price to book
- 3.55
- Dividend yield
- –
See a number that looks wrong?